Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
B cells and the therapeutic index of checkpoint blockade.
2026. nov. 2.· The Journal of clinical investigation· PUBMED
Publikáció
Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Vizsgálat
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.
2026. nov. 1.· Hematological oncology· PUBMED
Vizsgálat
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
2026. okt. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology.
2026. okt. 23.· Mucosal immunology· PUBMED
Publikáció
PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study.
2026. okt. 22.· Frontiers in oncology· PUBMED
Publikáció
The role of interleukins and immunological parameters in patients with colon cancer: an optical insight.
2026. okt. 22.· Lasers in medical science· PUBMED
Vizsgálat
A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
2026. okt. 20.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
CTLA-4/PD-1, LAG-3, and TIGIT Inhibitors: Emerging Drug Targets and Combination Strategies in Hepatocellular Carcinoma.
2026. okt. 20.· Current cancer drug targets· PUBMED
Publikáció
Association of immune checkpoint-related polymorphisms in PD-1, PD-L1, and CTLA-4 genes with susceptibility to genitourinary cancer: a meta-analysis.
2026. okt. 15.· Immunologic research· PUBMED
Publikáció
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial.
2026. okt. 6.· Nature communications· PUBMED
Vizsgálat
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
2026. okt. 3.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Preprint
Engineered CTLA-4 targeting chimeras for targeted protein degradation and immune synapse reprogramming.
2026. okt. 2.· bioRxiv : the preprint server for biology· PUBMED
Vizsgálat
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
2026. okt. 1.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publikáció
Anti-PD-1/CTLA-4 bispecific antibody-based combination therapy for cervical cancer: a multicenter study with biomarker analysis.
2026. okt. 1.· Frontiers in immunology· PUBMED
Publikáció
Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies.
2026. okt. 1.· Frontiers in immunology· PUBMED
Vizsgálat
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
2026. szept. 30.· PHASE2 · RECRUITING· CTGOV
Publikáció
Oncolytic virus VT1092M synergizes with immune checkpoint inhibitors against intraperitoneal metastases of colorectal cancer.
2026. szept. 30.· Frontiers in immunology· PUBMED
Publikáció
Impact of obesity on LAG-3 and CTLA-4 expression in CD4+ T cells from lymph nodes of sarcoidosis patients.
2026. szept. 25.· Immunobiology· PUBMED
Publikáció
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
2026. szept. 15.· Cancer research· PUBMED
Vizsgálat
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
2026. szept. 14.· PHASE2 · RECRUITING· CTGOV
Publikáció
Quantitative Systems Pharmacology Model Predicts Enhanced Antitumor Efficacy of Combined Cytotoxic T‑Lymphocyte-Associated Protein 4 (CTLA-4) and Programmed Cell Death Protein 1 (PD-1) Blockade in a Syngeneic Mouse Model of Breast Cancer.
2026. szept. 10.· ACS pharmacology & translational science· PUBMED
Vizsgálat
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
2026. szept. 9.· PHASE1 · RECRUITING· CTGOV
Publikáció
Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.
2026. szept. 5.· Nature communications· PUBMED
Publikáció
Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
2026. szept. 4.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Comparative Analysis of the Immune Profiles of Women and Men With Hepatocellular Carcinoma.
2026. szept. 1.· Cancer medicine· PUBMED